Core Insights - Kestra Medical Technologies, Ltd. reported a strong start to fiscal 2026 with revenue growth exceeding 50% in the first quarter [2] - The company is focused on expanding its market share in the wearable defibrillator market while enhancing operational capabilities [2] Financial Highlights - Total revenue for Q1 FY26 was $19.4 million, marking a 52% increase compared to the same period last year [8][9] - Gross margin improved to 45.7% in Q1 FY26 from 32.9% in the prior year period [8][9] - The company has increased its FY26 revenue guidance to $88 million, representing a 47% growth compared to FY25 [5][8] Operational Performance - 4,205 prescriptions were written for the ASSURE® system, reflecting a 51% increase year-over-year [9] - Revenue growth was attributed to higher market share with existing customers and the activation of new accounts [9] - Cash and cash equivalents stood at $201.2 million as of July 31, 2025 [9] Expenses and Losses - GAAP operating expenses were $37.7 million, which included $2.9 million of non-recurring costs related to being a new public company [9] - The GAAP net loss for Q1 FY26 was $25.8 million, compared to a net loss of $20.3 million in the prior year [9][14] - Adjusted EBITDA loss was $19.4 million, an increase from a loss of $15.7 million in the prior year [9][16]
Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results